Avastin treatments for macular degeneration have been found to be safe and effective for treating patients suffering from wet macular degeneration. The results of a new study published support the effectiveness and safety of using intravenous Avastin to treat macular degeneration.
In an uncontrolled study that examined 16 patients with wet macular degeneration that were treated with intravenous Avastin, it was shown that no serious systemic or ocular adverse events were identified.
In the study, one-half of the patients recieved a higher dose of Avastin (5 mg/kg) and the other half received a reduced dose of Avastin (2.5 mg/kg). All the patients had received three initial intravenous infusions of Avastin at 2-week intervals.
No serious systemic or ocular adverse events were identified following the injections of Avastin. It was also shown that there were no statistical differences between both treatments of Avastin. Both groups of patients suffering from macular degeneration had shown significant improvement in visual acuity and reductions in macular thickness that were sustained through 6 months.
The study authors have concluded that the visual acuity, optical coherence tomography and angiographic improves shown through the course of 6 months was evidence enough to follow-up and evaluate the long term durability of using Avastin as a treatment for macular degeneration.
This study showing that Avastin is safe as a macular degeneration may help eye care professionals promote the use of this drug when treating the eye disease.